Compare BATRA & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BATRA | ACAD |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 4.6B |
| IPO Year | N/A | 2004 |
| Metric | BATRA | ACAD |
|---|---|---|
| Price | $43.37 | $27.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 22 |
| Target Price | ★ $58.00 | $29.05 |
| AVG Volume (30 Days) | 54.4K | ★ 1.4M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.53 |
| EPS | N/A | ★ 1.54 |
| Revenue | $723,307,000.00 | ★ $1,047,118,000.00 |
| Revenue This Year | $12.40 | $15.16 |
| Revenue Next Year | $6.78 | $11.42 |
| P/E Ratio | ★ N/A | $17.62 |
| Revenue Growth | 6.62 | ★ 12.69 |
| 52 Week Low | $38.67 | $13.40 |
| 52 Week High | $50.50 | $27.73 |
| Indicator | BATRA | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 59.51 | 69.78 |
| Support Level | $42.06 | $26.38 |
| Resistance Level | $42.85 | $27.73 |
| Average True Range (ATR) | 0.64 | 0.83 |
| MACD | 0.13 | 0.14 |
| Stochastic Oscillator | 82.73 | 88.00 |
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.